Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.62 |
| ▸ | KIF11 | P52732 | 3/20 | 0.59 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490020 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL24489998 | 0.91 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL22461555 | 0.91 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL24490106 | 0.89 | KIF11 (0.52) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL24490102 | 0.89 | KIF11 (0.52) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL22460921 | 0.88 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL22460901 | 0.88 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL22460902 | 0.88 | KIF11 (0.53) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL22460919 | 0.88 | KIF11 (0.53) | SLC6A4SLC6A2SLC6A3KIF11RYR2 | |
| SCHEMBL24490016 | 0.86 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3KIF11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | SLC6A4 4468/4885SLC6A2 4575/4885SLC6A3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.